Home
/
VYNE Therapeutics Inc.
/
Financials
/
Quarterly
VYNE Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that VYNE Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2019
Sep 30, 2019
$0
Oct 31, 2019
Q2
2019
Jun 30, 2019
$0
Aug 1, 2019
Q1
2019
Mar 31, 2019
$0
May 2, 2019
Q3
2018
Sep 30, 2018
$0
Nov 7, 2018
Q2
2018
Jun 30, 2018
$0
Aug 1, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2025
Jun 30, 2025
$69.0K
Aug 14, 2025
Q1
2025
Mar 31, 2025
$202.0K
May 8, 2025
Q3
2024
Sep 30, 2024
$121.0K
Nov 7, 2024
Q2
2025
Jun 30, 2024
$198.0K
Aug 14, 2025
Q1
2025
Mar 31, 2024
$98.0K
May 8, 2025
Q3
2024
Sep 30, 2023
$114.0K
Nov 7, 2024
Q2
2024
Jun 30, 2023
$135.0K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$99.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$167.0K
Nov 13, 2023
Q2
2023
Jun 30, 2022
$126.0K
Aug 14, 2023
Q1
2023
Mar 31, 2022
$178.0K
May 11, 2023
Q3
2022
Sep 30, 2021
$133.0K
Nov 14, 2022
Q2
2022
Jun 30, 2021
$295.0K
Aug 12, 2022
Q1
2022
Mar 31, 2021
$230.0K
May 12, 2022
Q3
2021
Sep 30, 2020
$3.27M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$11.69M
Aug 12, 2021
Q1
2021
Mar 31, 2020
$1.75M
May 6, 2021
Q3
2020
Sep 30, 2019
$0
Nov 5, 2020
Q2
2020
Jun 30, 2019
$0
Aug 6, 2020
Q1
2020
Mar 31, 2019
$308.0K
May 11, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2025
Jun 30, 2025
($5.76M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($8.61M)
May 8, 2025
Q3
2024
Sep 30, 2024
($12.16M)
Nov 7, 2024
Q2
2025
Jun 30, 2024
($9.41M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($6.25M)
May 8, 2025
Q3
2024
Sep 30, 2023
($6.58M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($10.06M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($5.62M)
May 9, 2024
Q3
2023
Sep 30, 2022
($9.46M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($8.48M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
$4.67M
May 11, 2023
Q3
2022
Sep 30, 2021
($21.29M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($19.92M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($20.55M)
May 12, 2022
Q3
2021
Sep 30, 2020
($24.71M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($167.44M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($40.23M)
May 6, 2021
Q3
2020
Sep 30, 2019
($23.16M)
Nov 5, 2020
Q3
2019
Jun 30, 2019
($16.48M)
Oct 31, 2019
Q2
2020
Jun 30, 2019
($18.99M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2025
Jun 30, 2025
($7.54M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($9.20M)
May 8, 2025
Q3
2024
Sep 30, 2024
($13.09M)
Nov 7, 2024
Q2
2025
Jun 30, 2024
($10.40M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($7.38M)
May 8, 2025
Q3
2024
Sep 30, 2023
($6.23M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($10.32M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($5.88M)
May 9, 2024
Q3
2023
Sep 30, 2022
($9.33M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($8.29M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($8.69M)
May 11, 2023
Q3
2022
Sep 30, 2021
($10.77M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($9.54M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($9.76M)
May 12, 2022
Q3
2021
Sep 30, 2020
($23.49M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($167.18M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($39.89M)
May 6, 2021
Q3
2020
Sep 30, 2019
($23.20M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($19.36M)
Aug 6, 2020
Q1
2020
Mar 31, 2019
($15.88M)
May 11, 2020